Table 2.

Intracellular signalling in vascular and immune cells

Cell type/tissue	Receptor agonist	Intracellular target	Reference
HL-60	2-AG	MEK 1/2 → ERK 1/2, p38, Rho	(Kobayashi et al., 2001; Kishimoto et al., 2003)
Jurkat	JWH015	ERK 1/2	(Ghosh et al., 2006)
Human monocytes	JWH015	Akt, ERK 1/2	(Montecucco et al., 2008)
Human neutrophils	JWH133	ERK 1/2	(Montecucco et al., 2011)
Human coronary artery EC	JWH133, HU-308	NF-κB, Rho	(Rajesh et al., 2007a)
Human sinusoidal EC	JWH133, HU-308, HU-910	NF-κB?	(Batkai et al., 2007; Rajesh et al., 2007b; Horvath et al., 2012)
Human brain EC	JWH133, O-1966	NF-κB?	(Ramirez et al., 2012)
Human coronary artery SMC		Ras, p38 MAPK, ERK 1/2, SAPK/JNK, Akt	(Rajesh et al., 2008)
Mouse heart	JWH133	MEK 1/2 → ERK 1/2, JAK → STAT-3	(Montecucco et al., 2009)

HL-60, human promyelocytic leukaemia cell line; MEK, p44/42 MAPK (kinase activating ERK 1/2); SAPK, stress-activated protein kinase; ‘?’ depicts studies providing indirect evidence on the CB₂-dependent inhibition of NF-κB activation (e.g. inhibition of the expression of various adhesion molecules).